Will sgi-110 and astx727 walk hand in hand towards approval? I believe sgi-110 days are numbered. They are calling the new compound best in class. Bold words. Now will they spend the $100M on sgi-110? Reading the update, it seems behind the scenes on sgi-110 they knew they were in trouble. So to cushion the news, they needed a new direction. I believe this points at some serious problems with sgi-110. I pointed out how low a response rate they had. Pumpettees cannot understnad that survival with any drug, is predicated on statistics and if you have greater than 80% not responding, well that cannot be good for the final numbers.
First signs that your drug is in trouble. The need to expand late in the trial. That shows that you are not seeing the results needed to move forward. Second red flag, the need to expand the dosing from 3 days to 5 days to 10 days. The third red flag, adding CML to the mix late in the trial. Red flags.
Did you read the title of the release...the best in class in oral...well since there is no oral drug approved, they can make claims like this. They just have to show that this oral drug works a bit better in the lab. What happens in december now? My guess they may not move sgi-110 forward. They will also announce that they owe the astex boys $14M and burn is on the way. Here's something to ponder, why no astex compound moving up the line?
Pumpettees saw the announcement and already claiming victory. They do seem to get these things wrong, one more time will not make a difference. Best in class Oral hypomethylator is the words they read. Well pumpettees already have this approved and selling, even though they haven't dosed one single patient. The question that needs to be understood, will sgi-110 really move forward?
I guess if Dr. M was putting out a PR on my call at $6.92 to sell, he would be calling me the best in class in hyper pumpettee nonsense exposure. Bottom line your still $2.28 off the high.